Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236361 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 | |
| SCHEMBL23923715 | 0.83 | NPSR1 (0.45) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 | |
| SCHEMBL23923755 | 0.79 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 | |
| SCHEMBL3585184 | 0.78 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 | |
| SCHEMBL2565795 | 0.77 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 | |
| SCHEMBL3576836 | 0.77 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 | |
| SCHEMBL28527628 | 0.77 | ALDH1A1 (0.65) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 | |
| SCHEMBL3575872 | 0.77 | TUBB4A (0.65) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 | |
| SCHEMBL3036660 | 0.76 | CYP1A2 (0.70) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 | |
| SCHEMBL5229564 | 0.75 | MEN1 (0.61) | CYP1A2CYP2C9CYP2C19HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| WO-2012135669-A1 | NITROGEN RING CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | WEINGARTEN M DAVID (US) | 2012-10-04 | — | — | WO | disclosed |
| US-7897776-B2 | Sulfonamide containing compounds for treatment of inflammatory disorders | SALUTRIA PHARMACEUTICALS LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
| EP-2188272-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV Remynd (BE) | 2010-05-26 | — | — | EP | disclosed |
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20090270454-A1 | Sulfonamide containing compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| CN-1926137-A | Pyrrole-derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-03-07 | — | — | CN | disclosed |
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
| EP-1725550-A2 | PYRROLE-DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1670790-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005085239-A2 | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| EP-1568698-A1 | Pyrrole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030762-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | CYP1A2 67/4885CYP2C9 15/4885CYP2C19 2/4885 |
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RTF1, RNGTT, POLR2E | CYP1A2 802/4885CYP2C9 1249/4885CYP2C19 1050/4885 |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | CYP1A2 4573/4885CYP2C9 4880/4885CYP2C19 4845/4885 |
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | F12, F2, F5 | CYP1A2 182/4885CYP2C9 192/4885CYP2C19 176/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CYP1A2 2850/4885CYP2C9 4782/4885CYP2C19 4200/4885 |
| US-20090270454-A1 | Sulfonamide containing compounds for treatment of inflammatory disorders | STS, SULT2A1, CYP2S1 | CYP1A2 96/4885CYP2C9 239/4885CYP2C19 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.